This last one is a multikinase inhibitor that not only acts on angiogenic protein kinases (VEGFR-1, VEGFR-2, VEGFR-3, TIE-2), but as well on proteins involved in oncogenesis (KIT, RET, RAF-1, BRAF, BRAFV600), metastasis (PDGFR, FGFR), and tumor immunity (CSF1R) (192, 193). This evidence concerns the gene BRAF and neoplasm.